CTO: Dr. Alexander Greer
Dr. Greer brings to SingletO2 Therapeutics his expertise in the area of synthetic chemistry, kinetics, materials science, and bacterial inactivation methods. His current research is focused on singlet oxygen and its disease-fighting potential. He is professor of chemistry at Brooklyn College - City University of New York. His research is supported by funding from the National Science Foundation, the Petroleum Research Fund of the ACS, and has been supported the National Institutes of Health.
CEO: Dr. Alan Lyons
Dr. Lyons has a broad background in materials and processing techniques, with expertise in polymer science and engineering, surface science and photocatalysis. He has developed numerous approaches for fabricating polymer-based superhydrophobic surfaces. He is professor of chemistry at College of Staten Island and Graduate Center of the City University of New York, and his research is supported by funding from the National Science Foundation, NYSERDA/PowerBridgeNY, and the CUNY Center for Advanced Technology (CAT). Before joining CUNY, Dr. Lyons was a manager and Distinguished Member of Technical Staff at Bell Laboratories where he gained extensive industrial experience developing novel materials telecommunication products.